SGN-10. Seattle Genetics.

Abstract

Seattle Genetics is developing SGN-10 (BR96-SCIT), a single-chain immunotoxin (SCIT) under license from Bristol-Myers Squibb (BMS), as both a monotherapy and in combination with Taxotere (Rhône-Poulenc Rorer) for the potential treatment for cancer [308773]. SGN-10 is currently in phase I clinical trials [308773], [369809], [382807], [408963], [410348]. The compound is a follow-up to SGN-15 (BR96-DOX; BMS) and is potentially more effective and cheaper to manufacture. It delivers a bacterial toxin which is 250-times more potent than BR96-DOX and is one third the size, hence enabling tumor penetration more easily. BMS submitted an IND for SGN-10 in the first quarter of 1996 [200849], [204704]. BMS licensed the SCA-protein (single-chain antigen-binding protein) technology from Enzon in 1993 [352743]. In April 1998, Seattle Genetics completed a licensing agreement with BMS to take over development of SGN-10 [308773].

• Authors: S V Smith
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 9 Pg. 1314-9 (Sep 2001) ISSN: 1472-4472 [Print] England
• PMID: 11717821 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• BMS-191352 protein, recombinant
• Bacterial Toxins
• Exotoxins
• Recombinant Fusion Proteins
• Single-Chain Antibodies
• ADP Ribose Transferases

Topics

• ADP Ribose Transferases
• Animals
• Antibodies, Monoclonal
• Antineoplastic Agents (pharmacology, therapeutic use, toxicity)
• Bacterial Toxins
• Clinical Trials, Phase I as Topic
• Exotoxins
• Humans
• Neoplasms (drug therapy)
• Recombinant Fusion Proteins (pharmacology, therapeutic use, toxicity)
• Single-Chain Antibodies
• Structure-Activity Relationship